glp 1 and osa Frontiers The expanding scope of GLP-1
Description
DPP4 contributes to the degradation of incretin hormones, specifically glucagonlike peptide 1 (GLP1) and glucosedependent insulinotropic peptide (GIP), by cleavage of a dipeptide from their N termini
Tirzepatide exhibited the highest risk of gastrointestinal side effects, whereas dulaglutide and exenatide showed relatively better tolerability
These neurological changes also appear to extend beyond food for some people
Important but less common side effects include: Hypoglycaemia (low blood sugar) : particularly in patients with type 2 diabetes taking other glucose-lowering medications
Benefits include decreased exacerbation frequency, improved functional testing, and improved patient-reported quality of life
3qv and Extended Data Fig
